CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
Phase 1
Detroit, Michigan, United States and 4 other locations
A phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer...
Phase 1
Ann Arbor, Michigan, United States and 8 other locations
with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two pr...
Phase 2
Maumee, Ohio, United States and 2 other locations
to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...
Phase 3
Ann Arbor, Michigan, United States and 117 other locations
ARV-471 (PF-07850327) given together with palbociclib in advanced breast cancer. In particular, the study will compare the combinat ...
Phase 3
Ann Arbor, Michigan, United States and 39 other locations
This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their ...
Phase 3
Detroit, Michigan, United States and 226 other locations
body) and a treatment part. The primary purpose of the study is to see how (Z)-endoxifen works on tumor cell growth by monitoring a cancer...
Phase 2
Detroit, Michigan, United States and 9 other locations
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 a ...
Phase 1, Phase 2
Ann Arbor, Michigan, United States and 15 other locations
how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast...
Phase 3
Detroit, Michigan, United States and 118 other locations
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), ph...
Phase 1
Detroit, Michigan, United States and 16 other locations
Clinical trials
Research sites
Resources
Legal